@article{61f1741cfe7c46149219d46c783f6739,
title = "Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499",
author = "Smith, {M. R.} and F. Hong and H. Li and Gordon, {L. I.} and Gascoyne, {R. D.} and Paietta, {E. M.} and Advani, {R. H.} and A. Forero-Torres and Horning, {S. J.} and Kahl, {B. S.}",
note = "Funding Information: This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L Comis, MD and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180794, CA180820, CA180853, CA189859, CA180816, CA180855, CA180799, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. 90Y-ibritumomab tiuxetan was supplied by Spectrum Pharmaceuticals.",
year = "2017",
month = feb,
day = "1",
doi = "10.1038/leu.2016.305",
language = "English (US)",
volume = "31",
pages = "517--519",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",
}